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Summary Twenty-seven patients cured of advanced testicular cancer by cisplatin-based chemotherapy have
been assessed, a median of 30 months after start of treatment, for the long-term effects of such treatment on
renal, endocrine, audiometric, reproductive and respiratory function. To control for the effects of orchidec-
tomy on endocrine function a similar group of 11 patients cured by orchidectomy alone was also assessed. The
extents of impairment in hearing and renal function were related to the total dose of cisplatin received, while
the majority of patients had respiratory impairment which was, in part, related to the total dose of bleomycin.
TSH was significantly higher in the chemotherapy group although serum free thyroxine and free T3 were
normal in all. FSH was raised in 67% of the chemotherapy group and in 45% of the orchidectomy group
while LH was raised in 75% and 45% respectively. Serum testosterone was normal in all. The levels of FSH
and LH were both independently correlated with age of the patient while FSH was higher in patients having
more chemotherapy and had a tendency to fall towards normal with time since treatment. Over half the
patients had normal sperm concentrations although 74% had a raised proportion of abnormal sperm. Indices
of sperm function were worse in patients having more chemotherapy but sperm number increased towards
normal with time since treatment, particularly after the second year. The long-term side-effects of
chemotherapy for testicular cancer are thus generally mild but are largely irreversible and their severity is
related to the total amount of chemotherapy received. As their longer term significance is not clear we would
recommend that, in the treatment of testicular cancer, doses of chemotherapy are reduced to the minimum
required for cure. Assessment of long-term side-effects of chemotherapy for testicular cancer should be a
mandatory part of any study of such treatment and should be considered in any comparison of different
therapies.
Testicular cancer is increasing in frequency and is now the
most common registered malignancy in the age group 24-34
(Davies, 1981). Cisplatin-containing chemotherapy can, how-
ever, cure the majority of patients with advanced disease
(Einhorn & Williams, 1980; Newlands et al., 1980). Although
the immediate toxicity of such chemotherapy is well known,
its long-term effects may have more impact on the quality of
life of the increasing number of young men now being cured.
We have studied a group of patients who have received
chemotherapy for testicular cancer, with the aim of assessing
its long-term effect on renal, pulmonary, endocrine,
audiometric and reproductive function.
Patients and methods
Patient group
All patients of MHC and of Dr A.J. Banks who had received
chemotherapy for testicular cancer in the period 1979-1983
and who remained well with no sign of recurrent disease were
contacted by post and asked to take part in the study; 24 of
36 agreed. A further three had had post-chemotherapy
semenalyses and were only included in this part of the
analysis. One patient had a retroperitoneal teratoma and all
other patients had had an orchidectomy, and although no
pre-treatment semenalyses were done 10 had previously been
fertile as indicated by pregnancy in their partners. No patient
had hydronephrosis at presentation, six had non-bulky lung
metastases and one patient had retroperitoneal lymph node
dissection (RPLND) following chemotherapy. No patient
had received gentamicin during therapy.
In order to assess the effect of orchidectomy alone on
endocrine function a second group of 11 patients with stage I
teratoma, who were free of disease a median of 11 months
following orchidectomy, were selected from the patient list of
the same two consultants. These had serum free thyroxine,
free T3, TSH, LH, FSH and testosterone measured. The
characteristics of the study groups are shown in Table I.
Methods
Clinical notes were reviewed to obtain details of investiga-
tions at presentation and of chemotherapy received. Hepatic
and renal function, serum TSH, free thyroxine and free T3,
serum FSH, LH and testosterone, tumour markers (a-
fetoprotein and P-human chorionic gonadotrophin) and full
blood count were measured. Standard laboratory normal
ranges were used and serum hormones were measured by
specific immunometric methods.
Pulmonary function assessment comprised measurement of
vital capacity (VC), forced residual capacity (FRC), residual
volume (RV), total lung capacity (TLC), forced expiratory
capacity in one second (FEV,), peak expiratory flow rate
(PFR), transfer factor coefficient (KCO), total lung transfer
factor (TLCO), total alveolar volume (TAV) and effective
alveolar volume (EAV). TLCO was measured by single
breath-hold method with correction for haemoglobin concen-
tration, EAV by single breath helium dilution and lung
volumes by steady state helium dilution. Values other than
TAV and EAV were expressed as standardised residuals
(Miller & Pincock, 1988) with expected values determined
from height and age by published regression equations
(European Coal and Steel Community Recommendations,
1983). TAV and EAV have no expected value and were
expressed as absolute values.
Patients who had not had a vasectomy or RPLND (23/27)
were asked to have two semenalyses. In total 36 semenalyses
were done in 23 patients, 10 refusing second analysis. A
median of 46 weeks (range 22-57 weeks) elapsed between
semenalyses. Analyses were carried out after a mean of 4
days abstinence (range 2-14 days) with specimens produced
at the laboratory and analysed immediately. The following
indices were assessed according to standard criteria (WHO,
1987); volume of ejaculate, sperm number per ml, qualitative
motility, per cent of motile sperm, per cent live sperm and
per cent normal sperm. Mean values were used for patients
having two semenalyses. Qualitative motility was determined
subjectively by a trained observer and expressed as good,
medium or poor.
Audiometric assessment was undertaken in a sound treated
acoustic room with pure tone air conduction threshold deter-
mined for each ear at 0.5, 1, 2, 4, 6, and 8 kHz. Extent of
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Table I Characteristics of study groups
Chemotherapy Orchidectomy
group group
Median age at diagnosis
Median months between start of treatment and time of testa
Median number of courses of chemotherapy (range)
Mean total dose m-2 (range)
Cisplatin
Bleomycin
Vinblastine
Drug regimens
Cisplatin, vinblastine, bleomycin (PVB)
PB + etoposide
PVB + etoposide
PVB + actinomycin-D
PVB + etoposide + actinomycin-D
Drug schedulesb
Cisplatin by one hour infusion x I day
Cisplatin by one hour infusion x 5 day
Saline diuresis
Additional mannitol diuresis
Bleomycin bolus (i.v. or i.m.) day 1, 8, 15
Bleomycin infusion day 1-5
Mean change in weight since start of treatment (range)b
30 (20-51)
30 ( 7-63)
3( 2-11)
350 mg (150-680)
168 mg( 56 -386)
41 mg( 20- 80)
18
3
3
2
18
6
24
6
21
3
+4.5kg(-4 to + 18 kg)
aDate oftreatment = date oforchidectomy or start ofchemotherapy;bexcluding 3 patients whoonly had
semen analysis.
high-tone hearing loss was defined as the total hearing loss at
6 and 8 kHz averaged for the two ears.
Statistical methods
Statistical analysis was undertaken using the StatView
512+ microcomputer program (BrainPower Inc., 1986) with
logistic regression carried out using the BMDP suite of soft-
ware (BMDP Statistical Software, 1985). The relationship
between variables was assessed by linear regression to deter-
mine the value of b (slope) and of R2 or by Mann-Whitney
U test for the grouped variables, e.g. presence/absence of
lung metastases. Forward, stepwise, multiple regression
analysis was used where multiple significant associations were
found with logistic regression used when the dependent
variable was discontinuous (qualitative motility). The robust-
ness of the formula derived from forward, stepwise regression
was tested by backward elimination and by fitting all
variables in the model. Dependent variables used were doses
of cytotoxic drugs, number of courses of chemotherapy,
method of chemotherapy administration (infusion versus
bolus), age of patient, time since treatment and, for renal
function, weight change since treatment, for pulmonary func-
tion, whether the patient was a smoker or had lung meta-
stases and, for fertility, whether the patient had bulky
abdominal disease at presentation.
Results
Full blood count and biochemicalprofile
All patients had normal haemoglobin, white cell and platelet
count and red cell indices and had normal bilirubin, liver
enzymes and tumour markers.
Audiometry
There was a significant association between the extent of
high-tone hearing loss and the total dose of cisplatin received
per m2 (Figure 1). Despite this significant association the
correlation was modest and some patients had marked hear-
ing loss at relatively low cumulative doses of cisplatin while
others had little hearing loss after high doses. No association
was seen between high-tone hearing loss and age at treat-
ment, time since treatment, dose of cisplatin per course,
method of cisplatin administration or type of diuresis used.
Multivariate analysis confirmed that cumulative dose of cis-
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Figure 1 Association between total dose of cisplatin and extent
of high-tone hearing loss expressed as total hearing loss at 6 kHz
and 8 kHz averaged for both ears (b = 0.008, R2 = 0.2, P<0.03).
Patients who received additional mannitol diuresis shown by 0.
platin was the most highly correlated variable but also
showed that, after allowing for platinum dose, patients
receiving mannitol diuresis had less high-tone hearing loss
(entered at step 2, f-to-enter 5.5, P<0.001).
Pulmonaryfunction
All patients had normal PA chest radiograph. KCO was
below expected in all patients with a mean standardised
residual of - 1.7 (range -0.37 to - 3.37). Eleven (46%) of
the study group were below the lower 90% confidence inter-
val of the expected value. KCO, however, was not related to
the total dose of bleomycin received. VC and EAV each
showed significant inverse associations with number of
courses of chemotherapy received and with cumulative dose
of bleomycin (R2>0.22, P<0.02 in each case). These rela-
tionships are shown in Figures 2 and 3 respectively, which
also indicate which patients smoked prior to treatment.
Levels of VC and EAV were also lower in patients having
lung metastases (Z = -2.2, P<0.05 in each case). Mul-
tivariate regression showed that VC and EAV were most
highly associated with number of courses of chemotherapy
received and, after allowing for this, there was no residual
association with bleomycin dose, presence of metastases,
whether the patient smoked or the mode of admininstration
of bleomycin. Pulmonary function was also independent of
age and showed no tendency to return towards normal with
time after treatment.
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Figure 2 Association between total dose of bleomycin received
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Figure 3 Association between total dose of bleomycin received
and effective alveolar volume (b = -0.008, R2= 0.26, P<0.01).
Patients who smoked before treatment shown by 0.
Renalfunction
At the start of treatment none of the 24 patients had serum
urea or creatinine above the upper limit of normal
(7.5 mmol 1' and 125ltmol I-', respectively) while at the
time of follow-up two had serum urea and three serum
creatinine levels outside this range. The majority of patients,
however, showed serum creatinine and serum urea higher on
follow-up than before chemotherapy (21 of 24 and 18 of 24,
respectively). The extent of the change in serum creatinine
between pre-treatment values and follow-up values was
significantly related to the extent of treatment received
(number of courses of chemotherapy or total dose of cis-
platin received (Figure 4), R2> 0.32, P<0.005 in each case).
There was no significant association between any index of
renal function and age, weight change, type of diuresis used,
method of administering cisplatin or time since treatment.
Multivariate analysis confirmed that cumulative dose of cis-
platin was the only independently associated variable.
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Figure 4 Association between total dose of cisplatin and change
in serum creatinine between pre-treatment value and post-
treatment value (b = 0.1, R' = 0.44, P<0.001).
Endocrinefunction
The results of hormone assays are summarised in Table II.
Free thyroxine and free T3 levels were within the normal
range in all chemotherapy and orchidectomy patients
although two of 20 chemotherapy patients (10%) had raised
levels of TSH. The level of thyroxine and free T3 were
similar in the two groups but TSH was significantly higher in
the chemotherapy group. The level of TSH was independent
of age and time since treatment but was significantly
associated with the cumulative dose of cisplatin and vinblas-
tine (R2= 0.13, P = 0.05 in each case).
Sixteen of 24 patients in the chemotherapy group had
raised LH levels (67%) while 18 (75%) had raised FSH
levels. In the orchidectomy group 6/11 (55%) had raised LH
and the same number raised FSH, in neither case
significantly different from the chemotherapy group. All
patients had testosterone levels within the normal range.
Simple regression using both groups of patients showed the
levels of FSH to be related to the age of the patient
(R2 = 0.24, P<0.01), the number of courses of chemo-
therapy received (orchidectomy group = 0 courses, R' = 0.21,
P<0.01), and the cumulative doses of cisplatin, bleomycin
and vinblastine (orchidectomy group = 0 mg, R2>0.11,
P<0.05 in each case). Stepwise, multiple regression showed
that FSH was independently associated with the number of
courses of treatment (R2 = 0.21, P<0.01, Figure 5), the age
of the patient R2=0.36, P<0.01), and inversely with time
since treatment (R2=0.52, P<0.001). Levels of LH were
only associated with age of the patient a finding confirmed
on stepwise, multiple regression (R' = 0.21, P<0.01) which
showed no other independent associations.
Semen analysis
Table III summarises the results of semen analysis. Fifty-
seven per cent of chemotherapy patients had normal sperm
concentrations and, of the 19 who were not azoospermic, 17
Table II Serum hormone levels in chemotherapy and orchidectomy (control) groups
Normal Mean Standard Number with
Serum hormone value (range) deviation abnormal result
LH (chemotherapy group) <8 u 1- 16 (7-52) 12 16/24 (67%)
LH (orchidectomy group) 10 (6-19) 4 6/11 (55%)
FSH (chemotherapy group) <7 u I-' 16 (2-50) 12 18/24 (75%)
FSH (orchidectomy group) 11 (3-22) 7 6/11 (55%)
TSH (chemotherapy group) <5 mu I' 2.6 (0.5-5.7) 1.4 2/20 (10%)
TSH (orchidectomy group) 1.4 (0.3-4.2) 1.0 0/11
Free T3 (chemotherapy group) 2.0-8.0 pmol 1- 5.8 (4.2-6.9) 0.7 0/20
Free T3 (orchidectomy group) 5.4 (4.7-5.9) 0.4 0/11
Free thyroxine 90-240 nmol I- 132 (94- 197) 16 0/24
(chemotherapy group)
Free thyroxine 147 (125-179) 19 0/11
(orchidectomy group)
For FSH, LH, Free thyroxine and free T3 no significant difference. For TSH t = 2.4, P= 0.03.
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Figure 5 Association between serum FSH and number of
courses of chemotherapy received, orchidectomy group = 0
courses (b = 2.01, R2= 0.24, P<0.001).
(89%) showed normal numbers of motile and live sperm.
Three-quarters of patients, however, had a high proportion
of abnormal forms. Univariate regression showed that sperm
concentration was significantly associated with time since
treatment (Figure 6), a finding confirmed by multivariate
regression, which showed no independent association with
any other variable. Indices of sperm function (per cent motile
sperm, per cent live sperm, per cent normal sperm and
qualitative motility) were, however, significantly associated
with the amount of treatment received, i.e. number of courses
of chemotherapy or cumulative dose of cisplatin or vinblas-
tine but not with time since treatment. Stepwise, multiple
regression showed that for per cent live sperm and per cent
normal sperm the only independently associated variable was
the cumulative dose of vinblastine received (R2 = 0.37,
P<0.01, R2 = 0.23, P<0.05, respectively) while for per cent
motile sperm and qualitative motility it was the cumulative
dose of cisplatin (R2 = 0.32, P<0.02; f-to-enter = 20.43,
P<0.001, respectively).
Discussion
For patients with incurable cancer the immediate side-effects
of chemotherapy are clearly the most important and these
have received most study to date. Although such side-effects
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Figure 6 Association between sperm concentration and time
since start of chemotherapy, mean values plotted for patients
having two semenalyses. Patients who have fathered children
since chemotherapy shown by 0 (b = 0.335, R2 = 0.38,
P<0.002).
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may be severe they are essentially transient and last little
longer than the treatment. For patients with curable cancer
the long-term side-effects of chemotherapy may be more
important as these patients have to bear any such sequelae
for the rest of their lives. These long-term side-effects have
received less attention.
Audiometry
Previous studies have implicated a number of treatment-
related factors in the development of cisplatin ototoxicity, an
event which is irreversible. The duration of administration,
total dose and dose per course all seem to have some
influence (Piel et al., 1974; Helson et al., 1978; Reddel et al.,
1982; Schaefer et al., 1985). It may also be that individual
patients have different susceptibility to VIII nerve damage
(Aguilar-Markulis et al., 1981). Several studies have
emphasised the importance of cumulative total dose,
although the level above which ototoxicity was considered
significant ranged from 200 to 500 mgm2 (Reddel et al.,
1982; Chiuten et al., 1983; Schaefer et al., 1985). This study
confirms the importance of total cumulative dose with the
majority of patients receiving above 300 mgm-2 having
significant hearing loss. Some patients, however, received
higher cumulative doses with little hearing loss and our
analysis suggests that mannitol diuresis may have some pro-
tective effect. It is possible that individual susceptibility or
other factors not assessed in this study are involved in deter-
mining the extent of hearing loss. Others have shown greater
ototoxicity in those aged over 40 (Melamed et al., 1985), a
finding that we cannot confirm because of the small number
of such patients in this study.
Pulmonaryfunction
The capacity for bleomycin to cause potentially life-
threatening pulmonary fibrosis is well recognised (Yagoda et
al., 1972). Previous studies have recommended different
measures of pulmonary function for the acute assessment of
bleomycin toxicity. Vital capacity, alveolar volume, pul-
monary capillary blood volume and carbon monoxide
diffusing capacity have all been suggested as being good
measures of acute bleomycin lung damage (Van Barneveld et
al., 1984; Sorensen et al., 1985; Luursema et al., 1983).
Others have found pulmonary function testing to be unhelp-
ful (Lewis et al., 1980) with no dose-related change in lung
function during treatment (Bell et al., 1985). Fewer studies
have assessed long term pulmonary function in patients who
have received bleomycin. Lucraft et al., (1982) showed a dose
related fall in TLCO which persisted for at least 12 months
following treatment. The same study, however, showed no
change in other measures of pulmonary function when the
total dose of bleomycin was less than 360 mg. Luursema et
al. (1983) also showed no change in vital capacity during
treatment and up to two years afterwards. Patients in our
study all had values of KCO below predicted indicating that
the group as a whole had abnormal lung function following
treatment. The total dose of bleomycin received was not
related to the extent of impairment in KCO but was related
to lung volume measurements (VC, EAV). This is consistent
with, but not diagnostic of, a dose related lung fibrosis. In
summary, patients treated for teratoma with chemotherapy
have long term abnormalities ofpulmonary function that are,
at least in part, determined by the cumulative dose of
Table III Results of semen analysis
Index offertility Normal Median Standard Number with
value (range) deviation normal result
Million sperm ml ' >20 29 (0-150) 35 13/23 (57%)
Per cent of sperm motile" > 50% 58% (10-80) 15 17/19 (89%)
Per cent of sperm alive,' > 50% 65% (20-86) 15 16/18b (89%)
Per cent of sperm normal,, >45% 38% (10-55) 10 5/19 (26%)
Qualitative motility" medium/good - - 9/19 (46%)
'Excluding azoospermic patients, bnot assessed in one patient.TOXICITY OF CHEMOTHERAPY FOR TESTICULAR CANCER 483
bleomycin and we find no evidence that these abnormalities
tend to resolve with time.
Renalfunction
The tendency of cisplatin to induce renal damage is well
recognised although this can be minimised by inducing a
saline diuresis. In recent series the mean fall in glomerular
filtration rate during cisplatin therapy has been reported as
low as 0% (Swainson et al., 1985) and as high as 29% (Reece
et al., 1987), although with different schedules of treatment.
Previous studies have related the extent of cisplatin nephro-
toxicity to peak levels of ultrafiltrable platinum and thus to
duration of administration and dose received (Reece et al.,
1987). The question of cumulative toxicity is more controver-
sial. Some have reported cumulative and unpredictable neph-
rotoxicity (Goren et al., 1986) while others have related
cumulative toxicity to renal cortical platinum concentrations
(Stewart et al., 1985). Others have denied any cumulative
toxicity (Meijer et al., 1982; Chiuten et al., 1983) but have
either studied small numbers ofpatients or have defined renal
damage only when serum creatinine was above normal levels.
This study has looked at long-term changes and has used
each patient as his own control. We have shown that most
patients have a rise in creatinine since the start of therapy
and that the extent of this rise is related to the total dose of
cisplatin received but is unrelated to changes in body weight.
Although considerable doubt has been cast on the value of
serum creatinine for monitoring renal function during
chemotherapy when body mass and dietary protein intake
fluctuate greatly (Daugaard et al., 1988), in the stable pre-
treatment or long post-treatment situation an excellent cor-
relation between serum creatinine and GFR is seen
(Daugaard et al., 1988) and indeed some have suggested that
serum creatinine is the preferred measure of GFR (Payne,
1986). The rise in serum creatinine in this population is thus
considered to be due to renal damage which is largely deter-
mined by the cummulative dose of cisplatin. Although the
extent of the damage is small, with most patients having
serum urea and creatinine within the normal range, it can not
be assumed to be insignificant in the long-term. This study
also confirms previous findings that nephrotoxicity is irrever-
sible and, within the age range in this study, is independent
of age.
Thyroidfunction
We can find only one previous work assessing thryoid func-
tion following chemotherapy for testicular carcinoma. In this
Leitner et al. (1986) looked at 22 patients in complete remis-
sion a median of 24 months after VAB-6 chemotherapy and
showed a normal TSH in all. We confirm that the majority
of patients have normal thyroid function a median of 30
months after starting chemotherapy but show that a few have
raised TSH indicating increased pituitary drive and sub-
clinical thyroid dysfunction. More interestingly we show that
the popualtion who received chemotherapy had higher levels
of TSH than a similar group who did not. This also suggests
that there may be some subclinical thyroid damage as a
result of chemotherapy and merits further investigation.
Fertility
Chemotherapy has historically been considered to render
most patients infertile. It is now clear, however, that recovery
of fertility is common following cisplatin based chemo-
therapy for testicular cancer (Lange et al., 1983; Johnson et
al., 1984). This study confirms a recovery in sperm count
following chemotherapy with over half the study patients
having normal sperm concentration. This recovery appears
most marked in the third year after treatment (Figure 6) with
a majority ofpatients having normal sperm concentrations at
this time. We have also assessed a number of sperm charac-
terisitics which greatly influence feritility but are unable to
find any similar published work. We have shown one of the
determinants of the numbers of motile, normal and live
sperm and of qualitative sperm motility is the extent of
chemotherapy received with patients having higher
cumulative doses or a greater number ofcourses having more
abnormal values. It is also clear from this and other studies
that, if the final impact of chemotherapy on fertility is to be
determined, patients must be followed up for at least three
years and probably longer (Kreuser et al., 1986).
It has previously been reported that, following hemicastra-
tion for testicular cancer, many patients have raised LH and
FSH levels (Fossa et al., 1980). The majority of patients in
that study, however, had also received abdominal radiation.
The present study confirms raised LH and FSH in a group of
patients having orchidectomy only. Patients having
chemotherapy for testicular cancer commonly have raised
FSH (Fossa et al., 1986) although raised LH is not always
seen (Kareuser et al., 1986). This study shows that the pro-
portion of patients having raised gonadotrophins is greater,
and the extent of the rise more marked, in those who have
also had chemotherapy. The extent of the abnormality in
FSH is, in part, determined by the amount of chemotherapy
received. The pattern of raised FSH following chemotherapy,
falling toward normal, as seen in this study, has previously
been reported (Fossa et al., 1986) and parallels the recovery
in sperm count that we have documented. In this study the
abnormalities in LH and FSH were more marked in older
patients. This may represent an effect of age alone or may be
because older patients are more susceptible to the testicular
effects of chemotherapy.
This study shows that most patients having cisplatin-based
chemotherapy for testicular cancer have no severe long-term
side-effects. The majority of patients, however, have
measurable disturbance of hearing and of renal, endocrine
and pulmonary function as well as of fertility. Many of these
effects show an association with the amount ofchemotherapy
given and are thus likely to be signs of long-term dose-
related toxicity. As patients with more extensive disease tend
to receive more chemotherapy we cannot exclude the pos-
sibility that some of the abnormalities may be due to the
extent of disease. Apart from recovery of fertility these
abnormalities appear irreversible. Further follow-up is
needed to assess the full significance of these abnormalities
but, in the meantime, it would be appropriate, in the treat-
ment of testicular cancer, to reduce doses ofchemotherapy to
the minimum required for cure. Assessment of the long-term
side-effects of treatment should be a mandatory part of any
study of chemotherapy for testicular cancer and such side-
effects should be considered in any comparison of different
therapies.
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